BOEHRINGER-INGELHEIM
6.2.2020 08:32:09 CET | Business Wire | Press release
Boehringer Ingelheim announced today that its Respimat® re-usable inhaler device is the winner of the 2020 Pharmapack Eco-Design Award. The Pharmapack Awards celebrate the latest innovations from packaging companies within the drugs, medical devices, health products and veterinary drugs sectors.5
Respimat® re-usable is an enhanced version of the well-established Respimat® soft mist inhaler, providing benefits for the environment and patients.1,4 It significantly reduces waste and product carbon footprint (PCF)1,3,6 – while most disposable plastic inhaler devices need to be replaced after the medication provided is used up, Respimat® re-usable can be used with up to six medication cartridges before needing replacement.7,8,9 Respimat® is also propellant-free, meaning its CO2 emissions are 20 times lower than those of commonly used pressurized metered-dose inhalers.1,3 By 2025, it is expected that 776 tons of plastic waste and 14,300 tons of CO2 emissions will be prevented as a result of Respimat® re-usable. 776 tons of plastic waste equals more than 77.6 million 0.5-liter PET bottles.10 It was also designed to offer simplified handling, with an easy-to-read dose indicator, better grip for daily use and easy assembly, taking into account patient feedback.11
“We developed the Respimat® re-usable inhaler as part of our commitment to help patients and provide benefits beyond treatment,” said Dr. Paola Casarosa, Head of Global Therapeutic Areas at Boehringer Ingelheim. “Respimat® re-usable is the result of patient feedback, providing an inhaler with enhancements such as simplified handling and an easy-to-read dose indicator, and significantly reduced impact on the environment.11 A very important aim of Boehringer Ingelheim is to lower greenhouse gases and reduce waste, so we’re proud to be recognized for our efforts in this area.”
Boehringer Ingelheim views safeguarding the planet as an essential prerequisite wherever possible and maintains a focus on environmental protection.12 That is one of the major reasons Boehringer Ingelheim continues to invest in innovation and initiatives to protect the environment.12
Intended audiences:
This press release is issued from our Corporate Headquarters in Ingelheim, Germany and is intended to provide information about Boehringer Ingelheim’s receipt of the Pharmapack 2020 Eco-Design Award.
For references and notes to editors, please visit: http://www.boehringer-ingelheim.com/press-release/respimat-re-usable-wins-pharmapack-eco-design-award
View source version on businesswire.com: https://www.businesswire.com/news/home/20200205005611/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Smartstream Smart Agents Delivers 70% Reduction in Back-Office Investigation Time, Proving the Case for Autonomous Operations26.3.2026 10:30:00 CET | Press release
Smartstream, the trusted data solutions provider for leading global financial institutions and enterprises, today announces that Smart Agents - its agentic AI solution for bank back-office operations is delivering measurable, transformational impact, with pilot results showing a 70% reduction in investigation time per user, per break. As the industry accelerates toward a service as software (SaS) operating model, and allowing more work to get done from software solutions, Smartstream is embracing this approach with agentic AI. The results validate a fundamental shift in how financial institutions approach exception management. In one benchmark scenario, the manual processing of 500 exceptions, typically requiring 116 hours of team effort, was reduced to just a few hours under fully autonomous operations. This eliminates swivel-chair workflows and frees up teams to focus on risk oversight, decision making, and higher-value activities. Institutions continue to struggle with back-office w
Infobip Supports Thousands of Startups and Scaleups Through Startup Tribe Programme26.3.2026 10:00:00 CET | Press release
In the first five years of the programme, Infobip has provided significant value in products and services to members, helping them build and scale customer communications worldwide Global AI-first cloud communications platform Infobip, which is celebrating its 20th anniversary this year, has supported thousands of startups and scaleups from over 120 countries in the first five years of its Startup Tribe Programme. Infobip launched its Startup Tribe Programme in May 2021 to help mission-driven startups and scaleups to build and manage their customer communications and engagement strategy and grow their business. It does this by providing access up to $60,000 in credits for Infobip’s services and its global network of advisors, investors, and accelerators. In the first five year, Infobip has provided millions in the value of products and services to its programme members. By eliminating the need to build a global communications infrastructure from the ground up, Infobip’s programme enabl
LTM Positioned as a Leader in ISG’s Provider Lens™ Evaluation for Oracle Cloud and Technology Ecosystem 202526.3.2026 09:58:00 CET | Press release
Recognition highlights LTM’s leadership across key quadrants in the United States and Europe LTM, the Business Creativity partner to the world’s largest enterprises, has been recognized as a Leader in multiple quadrants in the ISG Provider Lens™ Oracle Cloud and Technology Ecosystem 2025 reports for both the United States and Europe by Information Services Group (ISG), a leading global technology research and advisory firm. The ISG Provider Lens™ study evaluates leading Oracle ecosystem service providers across critical capability areas, including: Professional Services Managed Services OCI Solutions and Capabilities LTM’s positioning as a Leader across key quadrants in both regions reflects its strong Oracle ecosystem expertise, AI-led transformation approach, and proven track record in delivering large-scale enterprise cloud modernization programs. In its 2025 study, ISG highlights that the Oracle ecosystem is undergoing a fundamental shift toward AI-native architectures, multicloud-
Bureau Veritas Strengthens Global Sustainable Finance Capabilities with Expanded Climate Bonds Approved Verifier Status26.3.2026 08:30:00 CET | Press release
Bureau Veritas, a global leader in Testing, Inspection, and Certification services (TIC), is pleased to announce the expansion of its geographical scope as an Approved Verifier under the Climate Bonds Standard and Certification Scheme. Additional offices in China, Japan, India, and France are now formally listed in the Climate Bonds Verifiers Directory. This expansion builds on Bureau Veritas’ established role since the approval of its Brazilian office in 2020, further enhancing its ability to support issuers with high-quality, independent verification services across key markets. “Our expanded presence as an Approved Verifier under the Climate Bonds Standard reinforces Bureau Veritas’ commitment to advancing credible, high‑integrity sustainable finance”, said Marc Roussel, Executive Vice President, Urbanization and Assurance at Bureau Veritas. “With verifier capabilities available across key markets, we continue to deliver local expertise with global assurance standards; boosting mark
Invivoscribe® Expands IVDR Portfolio with IdentiClone® Dx IGH Assay Certification26.3.2026 06:13:00 CET | Press release
IdentiClone® Dx IGH is the first IVDR-certified assay for the detection of clonal immunoglobulin gene rearrangements in patients with suspected B-cell lymphoproliferative disease. Invivoscribe, a global leader in precision diagnostics and measurable residual disease (MRD) testing, is proud to announce that its IdentiClone Dx IGH Assay has received In Vitro Diagnostic Regulation (IVDR) 2017/746 Class C certification in the European Union (EU). Commercial availability of the IVDR-certified assay is anticipated by early April 2026. The IVDR replaces the former In Vitro Diagnostics Directive (IVDD), introducing significantly more stringent requirements for clinical evidence, performance evaluation, traceability, and post-market surveillance. Under IVDR, in vitro diagnostic devices are classified according to risk from Class A (lowest risk) to Class D (highest risk). Class C devices, such as IdentiClone Dx IGH, are considered high-risk tests that play a critical role in disease diagnosis an
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom